Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

5-(4-Pyridyloxy)pyrazoles as TGF-βr1 Kinase Inhibitors

A compound, alkoxy technology, applied in the application field of preparing TGF-βR1 inhibitor drugs, can solve the problem of low simulated survival rate and so on

Active Publication Date: 2022-03-18
JIANGSU AOSAIKANG PHARMA CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In a clinical trial of metastatic urothelial carcinoma, patients with high expression of TGF-β gene responded to PD-L1 mAb and had a low simulated survival rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 5-(4-Pyridyloxy)pyrazoles as TGF-βr1 Kinase Inhibitors
  • 5-(4-Pyridyloxy)pyrazoles as TGF-βr1 Kinase Inhibitors
  • 5-(4-Pyridyloxy)pyrazoles as TGF-βr1 Kinase Inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0113] Example 1: Compound 1

[0114]

[0115] Step A: Compounds 1-1 (4.7 g, 38.47 mmol, 1 eq) and 1-2 (5.26 g, 40.40 mmol, 5.10 ml, 1.05 eq) were dissolved in 40 ml of acetic acid and reacted at 80°C for 12 hours. After the reaction was complete, the mixture was concentrated in vacuo to remove the solvent, diluted with water (100 mL) and the pH of the solution was adjusted to 7 using saturated aqueous sodium bicarbonate. Extracted with ethyl acetate (100 mL x 2). The organic phases were combined, washed with saturated brine (100 ml), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column separation to obtain compound 1-3. MS (ESI) m / z: 189.1 [M+H + ].

[0116] Step B: Dissolve 1-3 (1 g, 5.31 mmol, 1 eq) and 1-4 (768.70 mg, 5.84 mmol, 1.1 eq) in 10 mL of N,N-dimethylformamide and add carbonic acid Potassium (2.20 g, 15.94 mmol, 3 equivalents) was reacted at 120° C. for 6 hours. It was diluted with water (60 mL) and extracted with ethyl acet...

Embodiment 2

[0120] Example 2: Compound 2

[0121]

[0122] Step A: Compound 2-1 (19 g, 148.94 mmol, 16.24 ml, 1 eq) was dissolved in hydrazine hydrate (59.26 g, 1.16 mol, 57.53 ml, purity 98%, 7.79 eq), reacted at 120°C under nitrogen atmosphere 30 hours. The reaction solution was cooled to minus 10 degrees Celsius, a large amount of white solids precipitated, filtered, the filter cake was collected, and dried in vacuum to obtain compound 2-2. MS (ESI) m / z: 124.1 [M+H + ].

[0123] Step B: 2-3 (15.26 g, 181.48 mmol, 15.11 ml, 1.5 eq) was dissolved in 100 ml of methanol, and 2-2 (14.9 g, 120.99 mmol, 1 eq) was added dropwise at 0°C in methanol (60 milliliters) solution, reacted 4 hours at 25 degrees Celsius. Cool to 25°C, dilute with water (100 mL), and extract with dichloromethane (200 mL×2). The organic phases were combined, washed with saturated brine (100 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 2-4. MS (ESI) m / z: 208.0 [M+H + ]....

Embodiment 3

[0129] Example 3: Compound 3

[0130]

[0131] Step A: Dissolve compound 2-2 (3 g, 24.36 mmol, 1 eq) and 3-1 (4.15 g, 24.36 mmol, 3.91 ml, 1 eq) in glacial acetic acid (30 ml), react 1 at 120°C Hour. It was diluted with water (30 mL) and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (10 ml×2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 3-2. MS (ESI) m / z: 230.0 [M+H + ].

[0132]Step B: Compounds 3-2 (1 g, 4.36 mmol, 1 eq) and 1-4 (860.54 mg, 6.54 mmol, 1.5 eq) were dissolved in N,N-dimethylformamide (10 mL) , Potassium carbonate (1.81 g, 13.08 mmol, 3 equivalents) was added under a nitrogen atmosphere, and the nitrogen atmosphere was maintained at 120 degrees Celsius for 16 hours. It was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (60 ml), dried over anhydrous sodium sulfate, filtered, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a class of 5-(4-pyridyloxy)pyrazole compounds as TGF-βR1 inhibitors and their application in the preparation of TGF-βR1 inhibitor drugs. Specifically disclosed are compounds represented by formula (I), pharmaceutically acceptable salts or isomers thereof.

Description

[0001] This application claims the following priority: [0002] CN201910069936.2, the application date is January 24, 2019. technical field [0003] The invention relates to a class of 5-(4-pyridyloxy)pyrazole compounds as TGF-βR1 inhibitors and their application in preparing TGF-βR1 inhibitor drugs. Specifically disclosed are compounds represented by formula (I), pharmaceutically acceptable salts or isomers thereof. Background technique [0004] Transforming growth factor-β (Transforming growth factor-β, TGF-β) is a multifunctional growth factor superfamily with a wide range of biological activities, involved in early embryonic development, cartilage and bone formation, synthesis of extracellular matrix, inflammation, Interstitial fibrosis, regulation of immune and endocrine functions, tumor formation and progression. [0005] The TGF-β superfamily consists of a class of structurally and functionally related polypeptide growth factors, and TGF-β is one of the important me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D405/14C07D487/04A61K31/454A61P35/00
CPCA61P35/00C07D405/14C07D401/12C07D401/14A61K31/4439A61K31/444A61K31/497
Inventor 付翔宇丁照中胡利红陈曙辉
Owner JIANGSU AOSAIKANG PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com